Technology
Gene Delivery with Erythrocyte Derived Membrane
Advances in cell and gene therapy have shown great potential to treat cancer and genetic diseases. These therapies utilize genetic payloads such as DNA and mRNA, but the immune system can easily identify and clear these payloads. In addition, the lack of targeting presents another challenge to the success delivery into cells.
Coastar has developed an innovative cell membrane coating technology to protect genetic drugs from immune system clearance and enable them to be delivered to target with high precision, breaking a major bottleneck to the successful therapies of cancers and other diseases.
How It Works
We coat genetic drug payloads with a layer of cell membrane, which can shield the payloads from immune system detection and clearance.
Membrane lipid is purified from cells. The rest of the cells is removed and discarded.
The cell membrane stock is then combined with genetic drug payload using our proprietary coating process. The combined payload and coating constitute the product.
The Value Proposition
Coastar's cell membrane coating technology will bring a wide range of benefits to therapies of cancer and other diseases. Our value proposition is four fold, as depicted in this diagram
Higher Efficacy: avoiding immune clearance means more payload is delivered to disease site which results in enhanced efficacy
More Applications: Payloads can be systemically delivered to their targets, such as sites previously difficult-to-reach or metastatic tumors
Minimal Toxicity: Our coating is similar to blood transfusion in terms of toxicity
Lower Cost: Fewer antibodies are generated against the cell membrane coated payloads, which translates into lower dosage and lower cost